Dyne Reports Progress Building Next-Generation Exon Skipping Franchise In DMD

The company reported updated data from the Phase I/II DELIVER trial testing DYNE-251 in patients with Duchenne muscular dystrophy (DMD) and announced leadership changes.

efficacy
Dyne's DMD drug continues to show efficacy in Phase I/II • Source: Shutterstock

The drug development focus in Duchenne muscular dystrophy (DMD) has been on gene therapy recently, but Dyne Therapeutics is working to develop next-generation exon-skipping medications that would compete with Sarepta Therapeutics, Inc.’s established exon-skipping franchise, including Exondys 51 (eteplirsen).

Key Takeaways
  • Updated data from a Phase I/II clinical trial DELIVER testing DYNE-251 in patients with DMD demonstrated greater dystrophin expression than what was seen in clinical trials for Sarepta’s Exondys 51.

The company announced updated data on 3 September from the ongoing Phase I/II DELIVER trial testing DYNE-251 in patients with...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

Kailera Eyes Global Obesity Market With Hengrui’s Phase III Dual Agonist

 
• By 

With China’s Hengrui reporting successful Phase III data for its dual GLP-1/GIP agonist, licensee Kailera is readying plans to demonstrate better efficacy than current obesity drugs.

Sellas Targets Tambiciclib To Adverse-Risk Frontline AML Patients After Phase II Success

 

The biotech announced positive Phase II data for the drug combined with AbbVie/Roche’s Venclexta and BMS’s Vidaza in relapsed/refractory acute myeloid leukemia.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

More from R&D

Bayer’s Kerendia Gains Blockbuster Indication For Heart Failure

 
• By 

New US approval in heart failure with preserved or mildly reduced ejection fraction should add to Kerendia’s earning power on top of chronic kidney disease indication.

Takeda Prepares Ground For Oveporexton In Narcolepsy

 

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Phase III Success For AstraZeneca’s $5bn Hypertension Hope Baxdrostat

 

Rivals Mineralys could be first to file but AstraZeneca is banking on its cardiovascular market know-how to lead the emerging class.